OGT announces expansion of Cytocell operations in the UK

Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced that it is expanding its Cytocell® operations with a move to a new facility in Cambridge, UK.

Cytocell, OGT’s fluorescence in situ hybridization (FISH) probe brand, will be moving into the significantly larger facility on the prestigious Cambridge Science Park, due to the expansion of the organization, current sales volumes and predicted sales growth.

In addition to investing in OGT by expanding Cytocell’s operational footprint, OGT’s parent company, Sysmex, is demonstrating its confidence in the UK by establishing the new premises.

OGT’s Cytocell brand provides the largest range of high-quality, reliable, and cost-effective FISH probes on the market and is well known for its comprehensive range, exceptional customer support, service and expertise.

Over recent months, OGT has been expanding the direct sales of Cytocell products in Europe and Asia. Staff numbers across the organization are increasing and a larger space is needed for manufacturing and logistics facilities to match the increased volume of product manufacture and shipment.

The new facility will have approximately three times the floor space of the current premises and capabilities to deliver a significant increase in output as the business continues to grow. OGT also plans to create a training and demonstration facility in the new premises to host its customers.

We’re delighted to announce the investment in, and expansion of, our Cytocell operations by Sysmex. Sysmex is committed to growing our business and aligning our commercial synergies. In addition, Sysmex is demonstrating its confidence in the UK’s strong traditional base in Life Sciences.

Our ever-growing cooperation with Sysmex delivers the benefits of being part of a larger organization to our customers, providing them with enhanced services and support."

John Anson, CEO

In addition to investing in OGT’s Cytocell brand, Sysmex is considering creating a global R&D facility at the premises to evaluate new technologies and pursue collaborations with key opinion leaders, resulting in delivery of innovative new products to the market.

Our acquisition of OGT has been, and continues to be, extremely successful. We are very much aligned in our goals and our synergies make for an excellent collaboration. This significant investment in the company is testament to our confidence and desire to further develop OGT’s brands alongside our portfolios".

Kenji Tsujimoto, Executive VP of Technology Strategy, Sysmex Corp​

OGT anticipates the new facility to be fully operational by May 2019.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Oxford Gene Technology. (2019, June 19). OGT announces expansion of Cytocell operations in the UK. News-Medical. Retrieved on October 04, 2023 from https://www.news-medical.net/news/20190227/OGT-announces-expansion-of-Cytocell-operations-in-the-UK.aspx.

  • MLA

    Oxford Gene Technology. "OGT announces expansion of Cytocell operations in the UK". News-Medical. 04 October 2023. <https://www.news-medical.net/news/20190227/OGT-announces-expansion-of-Cytocell-operations-in-the-UK.aspx>.

  • Chicago

    Oxford Gene Technology. "OGT announces expansion of Cytocell operations in the UK". News-Medical. https://www.news-medical.net/news/20190227/OGT-announces-expansion-of-Cytocell-operations-in-the-UK.aspx. (accessed October 04, 2023).

  • Harvard

    Oxford Gene Technology. 2019. OGT announces expansion of Cytocell operations in the UK. News-Medical, viewed 04 October 2023, https://www.news-medical.net/news/20190227/OGT-announces-expansion-of-Cytocell-operations-in-the-UK.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
OGT develops targeted NGS panel for constitutional cytogenetics research